Special Issue

Novel Models Targetting Vaccines and Drugs for *M. tuberculosis*, *M. avium* and *M. absessus* Infection

Message from the Guest Editors

A deeper understanding of acquired and suppressive immunity against *M. tuberculosis, M. avium,* and *M. abscessus* is required to shed light on protective immunity, which may enable effective vaccine and therapeutic compound treatment. The common threads of *Mtb, M. avium,* and *M. abscessus* are the ability to infect through aerosol exposure, the increased capacity to develop drug resistance, and the lack of a cure. These mycobacterial pathogens, *Mtb, M. avium,* and *M. abscessus,* are evolving and pose a potential threat to global human health. Novel infection models to understand the mechanisms of immune evasion, new drug regimens, and new vaccines are urgently needed. Keywords include, but are not limited to:

- M. tuberculosis
- M. avium
- M. abscessus
- novel infection models
- new vaccines and drugs

Guest Editors

Dr. Diane J. Ordway

Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA

Dr. Deepshikha Verma

Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA

Deadline for manuscript submissions

closed (22 November 2021)



Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/74297

Microorganisms
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
microorganisms@mdpi.com

mdpi.com/journal/microorganisms





Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

